As of November 6, 2026, Syndax Pharmaceuticals Inc is a publicly traded company (Nasdaq: SNDX); its largest reported holder is Goldman Sachs, with 6.5% on Schedule 13G/A of August 13, 2025, then State Street (6.4%). The largest insider holding is Michael A. Metzger, the chief executive and a director, with 484,843 shares (0.54% of shares outstanding), per Form 4 of July 9, 2026 (Schedule 13G/A, August 13, 2025).
Is this your company?
About to sign with, pay or invest in Syndax Pharmaceuticals Inc? See the free Snapshot first.
Free to see. No signup.
Is Syndax Pharmaceuticals Inc a real, registered company?
- Syndax Pharmaceuticals Inc files with the SEC under CIK 1395937 (its SEC filings).
- Its shares are listed under the ticker SNDX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under SYNDAX PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Keith A. Goldan, Chief Financial Officer (Form 8-K filed 2026-11-02). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names State Street (filed 2026-08-07).
Who are Syndax Pharmaceuticals Inc's owners and officers?
Syndax Pharmaceuticals Inc: incorporated in Delaware; business address in New York, New York; industry Pharmaceutical Preparations (Form D, 2026-11-02).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-07 | State Street Corporation | 6.4% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 2.3% |
| Schedule 13G, 2026-04-30 | Vanguard Capital Management | 5.05% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G, 2026-02-09 | State Street Corporation | 5.3% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 7.16% |
| Schedule 13G, 2025-08-18 | Point72 Asset Management, L.P. | 5% |
| Schedule 13G/A, 2025-08-14 | Point72 Asset Management, L.P. | 2.7% |
| Schedule 13G/A, 2025-08-13 | The Goldman Sachs Group, Inc. | 6.5% |
Questions about who owns Syndax Pharmaceuticals Inc
Who owns Syndax Pharmaceuticals Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Syndax Pharmaceuticals Inc: The Goldman Sachs Group, Inc. (6.5%, Schedule 13G/A, filed 2025-08-13), State Street Corporation (6.4%, Schedule 13G, filed 2026-08-07) and Vanguard Capital Management (5.05%, Schedule 13G, filed 2026-04-30).
Who are the largest shareholders of Syndax Pharmaceuticals Inc?
By the share each holder's latest filing reports, the largest holders of Syndax Pharmaceuticals Inc on this page are The Goldman Sachs Group, Inc. (6.5%), State Street Corporation (6.4%) and Vanguard Capital Management (5.05%).
When did The Goldman Sachs Group, Inc. buy into Syndax Pharmaceuticals Inc?
The filings give report dates, not purchase dates. The earliest filing from The Goldman Sachs Group, Inc. on this page is the Schedule 13G/A, filed 2025-08-13, reporting 6.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Syndax Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Syndax Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Syndax Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-02 | Keith A. Goldan | Chief Financial Officer | departed | 2026-11-09 |
Which insiders own Syndax Pharmaceuticals Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 484,843 shares (0.54% of shares outstanding) (Form 4, 2026-07-09).
- , a director: 239,763 shares (0.27% of shares outstanding) (Form 4, 2026-10-30).
- , the chief financial officer: 139,252 shares (0.16% of shares outstanding) (Form 4, 2026-06-02).
- , a director: 124,000 shares (0.14% of shares outstanding) (Form 4, 2026-02-06).
- , a director: 114,000 shares (0.13% of shares outstanding) (Form 4, 2026-02-06).
Shares outstanding: 89,297,086 as of 2026-07-31, from the company's latest SEC cover page.
How much has Syndax Pharmaceuticals Inc raised?
No fundraising or offering filing from Syndax Pharmaceuticals Inc is on file with us.
Keep reading
More on Syndax Pharmaceuticals Inc and the records around it.
Syndax Pharmaceuticals Inc elsewhere on the record
- Leadership changes Jun 2026
Companies that share a holder
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
- THE GOLDMAN SACHS GROUP, INC. also filed stake reports on 173 other companies: AEON ACQUISITION I CORP. (Nov 2026), ALPEX ACQUISITION CORPORATION (Nov 2026), ARCHIMEDES TECH SPAC PARTNERS II CO. (Nov 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/syndax-pharmaceuticals